

### 7. 510(k) Summary of Safety and Effectiveness:

OCT 2 3 2006

#### Submitter Information: A.

Submitter's Name:

Davol, Inc.

Address:

Subsidiary of C. R. Bard, Inc.

100 Sockanossett Crossroad

Cranston, RI 02920

Telephone:

(401) 215-2642

Fax:

(401) 215-2031

Contact Person:

Gail Dow

#### В. **Device Name:**

Trade Name:

Bard Composix® L/P Mesh

Common/Usual Name: Surgical Mesh

Classification Name:

Surgical Mesh, Polymeric

#### C. **Predicate Device Names:**

- Bard Large Pore Soft™ Mesh Pre-Shaped, K052155 (Davol Inc.), FDA cleared on 10/20/2005;
- Bard Composix® E/X Mesh, K002684 (Davol Inc.), FDA cleared on 10/11/2000;
- Davol Delivery System (currently marketed as PrecisionPass Laparoscopic Delivery Device), K041641 (Davol Inc.), FDA cleared on 07/01/2004.

#### D. **Device Description:**

The Composix® L/P Mesh, will consist of a layer of polypropylene mesh and a layer of expanded polytetrafloroethylene (ePTFE) stitched together using Polytetrafluroethylene (PTFE) monofilament thread sewn in a lock stitch formation. The polypropylene layer is knitted from 0.0048 inch polypropylene monofilament, which is identical to the currently marketed Large Pore Soft™ Mesh. The thickness of the ePTFE layer is identical to the currently marketed Composix® E/X Mesh. As with the currently marketed Composix E/X, the peripheral edge of the polypropylene mesh will be heat sealed to the ePTFE layer.

The layers of the Composix L/P Mesh will be sewn together using rows of interspaced stitching, which will allow the surgeon to tailor the product. Using the stitch pattern as a guide, the surgeon can tailor the product. For user convenience to facilitate the

deployment of the larger sized **Composix** L/P products, the larger sizes of the **Composix** L/P products will be packaged with an Introducer Tool. This Introducer Tool is similar to the rolling tines/plunger assembly and T-handle of the PrecisionPass<sup>TM</sup> Delivery Device. The Introducer Tool consists of a handle with a thin stainless steel rod. The stainless steel rod is split into two pieces along its length and has ridges around the perimeter to facilitate use. Similar to the T-handle provided with the **PrecisionPass** Device, the Introducer Tool's T-cap will be used to secure the open end of the metal rolling tines during the rolling process, then removed prior to delivering the device through the trocar.

## E. Intended Use:

**Bard** Composix® L/P Mesh is indicated for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias and chest wall defects.

# F. Summary of Similarities and Differences in Technological Characteristics, Performance and Intended Use

**Bard** Composix® L/P Mesh and the Predicate mesh have the same indication: reinforce soft tissue, i.e., repair of hemias and chest wall defects.

The Proposed Product has similar physical attributes, performance characteristics, and materials as the Predicates **Bard** Composix® E/X and **Bard** Large Pore Soft™ Mesh. Furthermore, it has similar manufacturing methods as the Predicate **Bard** Large Pore Soft™ Mesh and Predicate **Bard** Composix E/X Mesh.

The key differences in the Proposed Product as compared to the Predicate Products, is that the Predicate Bard Large Pore Soft™ Mesh Product is a large pore singlelayer polypropylene monofilament mesh and the Proposed Product is a bilayer construction. While both the Predicate Bard Composix E/X Mesh and the Proposed Product Bard Composix® L/P Mesh are similar in their bilayer construction, the two products combine different types of knitted polypropylene mesh with the same ePTFE layer. The Predicate Bard Composix E/X Mesh utilizes 0.006" Bard Flat Mesh with ePTFE, and the Proposed Product Bard Composix® L/P Mesh uses the 0.0048" Predicate Bard Large Pore Soft™ Mesh with a layer of ePTFE. In addition, the larger sizes of the Proposed Product Bard Composix® L/P Mesh will be packaged with an Introducer Tool. The Bard Composix® L/P Mesh Introducer Tool will facilitate rolling the device with a consistent technique; this will allow a low-profile device to be placed through the appropriate trocar sizes. The mesh side is visually distinguishable from the ePTFE side to determine correct prosthetic orientation. This is standard practice, similar to the other Composix® line products. Furthermore, the Introducer Tool is similar to the tines packaged with the Precision Pass

tool. The Precision Pass tool is packaged separately but often used jointly with the **Bard** Composix® E/X. The mode of operation, physical attributes, performance characteristics and materials of the **Bard** Composix® L/P Mesh Introducer Tool packaged with the larger sizes of the are all similar to the **Davol** Delivery System (Precision Pass tool).

## G. Performance Data

Biocompatibility and bench testing provided in this submission support the safety and effectiveness of **Bard** Composix® L/P Mesh for its intended use. The biocompatibility testing completed on the product manufactured with the same materials and similar processes as the **Bard** Composix L/P Mesh demonstrate the device is non-toxic and non-sensitizing to biological tissues consistent with its intended use. Laboratory testing discussed in this submission demonstrate that the material chosen and the design utilized in manufacturing **Bard** Composix® L/P Mesh is substantially equivalent to the referenced Predicate Products.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Davol Inc. % Ms. Gail Dow Regulatory Associate 100 Sockanossett Crossroad Cranston, Rhode Island 02920

OCT 2 3 2006

Re: K061754

Trade/Device Name: Bard® Composix® L/P Mesh

Regulation Number: 21 CFR 878.3300 Regulation Name: Surgical mesh

Regulatory Class: II Product Code: FTL Dated: October 3, 2006 Received: October 5, 2006

Dear Ms. Dow:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

## Page 2 – Ms. Gail Dow

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Mark N. M

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

K061754

## Indications for Use

Premarket Notification for the Bard® Composix® L/P Mesh

510(k) Number (if known): Unknown

Device Name:	Bard® Co	omposix® L/P	Mesh		
Indications for U	se:				
				ction of soft tissue	
deficiencies, su	uch as for the rep	pair of hernias	and chest wall de	fects.	
·					
			,		
•					
•					
Prescription Use _	<u> </u>	AND/OR	Over-The-Co	unter Use	
(Part 21 CFR 801 Sub	opart D)	(21 CFR 801 Subpart C)			
(PLEASE DO N	OT WRITE BELOW	THIS LINE-CON	TINUE ON ANOTHER	PAGE IF NEEDED)	
		Made	n -		
Co			n-Off) Device Evaluation eneral, Restora	(ODE)	
	a	nd Neurolog	gical Devices	FDA Page 1 of 1	
		40.41.	er. 120617	<del>5</del> 4	
Davol Inc.		510(k) Number 12 001 43		000	010